The o2h Human Health SEIS Fund - SEIS Investment Opportunities

The human health SEIS fund will invest in seed stage SEIS qualifying companies covering novel drug discovery along with enabling services, tools and AI Technologies. Next closing is on 31st March 2023.

Invest

Download Info Pack

featured in

highlights

                            The SEIS fund will invest in companies covering novel drug discovery along with enabling services, tools and AI technologies that can impact human health.
Minimum investment amount for investor is £ 10k.
The geographic scope shall be UK wide but will target the growing Cambridge biotech cluster which is now the global headquarters of AstraZeneca, and is home to many biotech companies some of which have subsequently been snapped up by large pharmaceutical companies.
The fund has a closing date of 31st March 2023 and is targeting significant or full deployment by the end of the tax year. We will develop a portfolio of at least 3 companies.

fund overview

Fund Status	Open, Closing on 31st March 2023
Fund Size	£ 1.5m
Current AUM	£ 500k
Maximum Subscription	£ 100,000
Expected Exit	3-7 years
Founder's Investment	Minimum 10% of every investment

Contact Download Info Pack

SEIS tax relief is very attractive for UK tax payers

You invest £50k

SEIS gives you £25k tax relief from HMRC

COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £25k income tax relief

- £10k performance incentive

= £65k net profit

VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £25k income tax relief

- £0 performance incentive

= £25k net profit

COMPANY FAILS

Investment now worth £0

£50k loss

+ £25k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £9,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

why o2h ventures?

+History in grassroots science: We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.

+Evaluation: Since its inception, the o2h group has developed a rigorous process to evaluate its deal flow, particularly regards seed investments. Opportunities come from a wide range of sources, as a result of the o2h group’s extensive network of contacts.

+Access to scientific talents: The team have developed access to some of the most interesting scientific ideas and talent in the UK, achieving a clearly differentiated position through its live working relationships, fostered over many years, working as a discovery services company. This potentially fives o2h ventures earlier access than competitor to some of the most promising companies.

+Business model: The business model identified by o2h ventures gives it an edge both in terms of access to opportunities as well as an understanding of the support they require post investment in terms of incubation. By combining access and incubation we are providing a unique opportunity, reducing investment risk by being deeply involved and the team believe that this will increase Fund’s prospects of making successful exits.

fund registered with